Global Custom Market Research Reports Provider Company

phone

AB Science SA (AB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Published Date: 23 Oct 2018
  • Number of Pages: 77
  • Category: Company Profile
  • Country: France
Summary

AB Science SA (ABS) is a pharmaceutical company focused on discovery, development, and commercialization of protein kinase inhibitors. The companys lead compound Masitinib, is a orally administered tyrosine kinase inhibitor targeting mast cells and selected kinases, including c-Kit, PDGFR, and Lyn in several human indications such as oncology, inflammatory diseases, and central nervous system diseases. The company is commercializing its lead product candidate in human and veterinary medicine. ABS has also developed KIT816 for the treatment of aggressive mastocytosis, seminoma, and acute myeloid leukemia; and syk for rheumatoid arthritis, b-cell lymphoma, and others. The company has operations in France and the US. ABS is headquartered in Paris, France.

AB Science SA (AB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons To Buy


Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Publisher Name : GlobalData


List of Tables 5
List of Figures 5
AB Science SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AB Science SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AB Science SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AB Science SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AB Science SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AB Science SA, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
AB Science Raises USD20.5 Million in Private Placement of Shares 11
AB Science Raises USD16.2 Million in Private Placement of Shares 12
AB Science Raises USD8 Million in Public Offering of Shares 13
AB Science Raises USD13.5 Million in Private Placement of Shares 14
Debt Offering 16
AB Science Completes Private Placement Of Bonds Due 2019 For US$13 Million 16
AB Science SA - Key Competitors 17
AB Science SA - Key Employees 18
AB Science SA - Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Financial Announcements 20
Oct 01, 2018: AB Science reports its revenues for the first half of 2018 20
Apr 30, 2018: AB Science reports its annual financials as of 31 December 2017 and provides an update on its activities 24
Aug 31, 2017: AB Science: Revenue Report For First Half of 30 June 2017 30
Aug 31, 2017: AB Science reports its revenue for the first half of 2017 34
May 01, 2017: AB Science Reports its Annual Financials as of 31 December 2016 and Provides an Update on its Activities 40
Product News 47
09/28/2017: AB Science announces that abstracts reporting on clinical and preclinical data of masitinib in the treatment of ALS, have been selected for presentation at 6 major international meetings during 2017 47
09/14/2017: AB Science announces that CHMP adopted a negative opinion for masitinib marketing authorization in indolent systemic mastocytosis after reassessment 50
05/28/2018: AB Science provides update on EU marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosis 51
05/18/2017: AB Science Announces Refusal of the marketing authorisation for Masipro (masitinib) 52
05/17/2017: AB Science announces that CHMP has adopted a negative opinion for masitinib in indolent systemic mastocytosis, primarily due to GCP inspection findings 53
04/19/2018: AB Science announces that the CHMP has adopted a negative opinion for the marketing authorization of masitinib in Amyotrophic Lateral Sclerosis 55
03/22/2018: EPFL: Attacking lymphoma at the source 56
03/20/2017: AB Science announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis 57
Clinical Trials 59
Jan 04, 2018: AB Science announces that based on interim analysis, IDMC recommended the continuation of the masitinib phase 3 study in progressive multiple sclerosis with no requirement to increase the sample size 59
Nov 21, 2017: Preclinical data published in Nature Communications shows that masitinib is capable of counteracting resistance to oncology treatments, including gemcitabine 60
Oct 19, 2017: Preclinical data showing protective effect of masitinib on the peripheral nervous system in ALS published in the Journal of Clinical Investigation Insight 62
Jun 22, 2017: AB Science Presents Supportive Data from its Phase 3 Study in Severe Systemic Mastocytosis at the 22nd Congress of the European Hematology Association 64
May 18, 2017: AB Science Presents Phase 3 Data for Masitinib in Amyotrophic Lateral Sclerosis at the European Network For The Cure of ALS Annual Meeting 66
May 12, 2017: AB Science announces that ANSM requested the temporary suspension of clinical studies conducted in France following deviations from Good Clinical Practice standards 68
Mar 29, 2017: AB Science announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years 70
Mar 07, 2017: AB Science Announces That Frontiers In Aging Neuroscience Publishes A Comprehensive Review On The Future Potential Of Masitinib In Amyotrophic Lateral Sclerosis 71
Mar 06, 2017: AB Science announces completion of patient recruitment for phase 3 study in severe persistent asthma 72
Jan 09, 2017: AB Science announces publication in The Lancet of phase 3 clinical trial results demonstrating masitinib is effective and well tolerated in the treatment of adult patients with severe indolent systemic mastocytosis 73
Jan 03, 2017: New Preclinical Data Demonstrate That Masitinib Has An Unexpected Protective Effect On Muscles And Nerves In Amyotrophic Lateral Sclerosis 75
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77

List Of Tables


AB Science SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AB Science SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AB Science SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AB Science SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AB Science SA, Deals By Therapy Area, 2012 to YTD 2018 9
AB Science SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AB Science Raises USD20.5 Million in Private Placement of Shares 11
AB Science Raises USD16.2 Million in Private Placement of Shares 12
AB Science Raises USD8 Million in Public Offering of Shares 13
AB Science Raises USD13.5 Million in Private Placement of Shares 14
AB Science Completes Private Placement Of Bonds Due 2019 For US$13 Million 16
AB Science SA, Key Competitors 17
AB Science SA, Key Employees 18
AB Science SA, Subsidiaries 19

List Of Figures


AB Science SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AB Science SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AB Science SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AB Science SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AB Science SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AB Science SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
AB Science SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AB Science SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Siemens AG (Siemens) is a technology company that offers products and solutions for electrification, automation and digitization. The company offers products, services and solutions for power generation, transmission and distribution;

View Report

UDG Healthcare plc (UDG) formerly, United Drug plc is a provider of outsourced commercial solutions to healthcare companies. It offers supply chain, packaging, sales and marketing, medical and regulatory services

View Report

Oxurion NV(Oxurion) formerly known as ThromboGenics NV, is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The companys ocriplasmin, a recombinant derivative of the plasmin protein, is

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports